Evidence map›Paper›PMID 39722558›Full record

Trial reportCPT: pharmacometrics & systems pharmacology2025

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma.

Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sebastien Benzekry

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02268695 (TPExtreme), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02268695 phase2completednot on this map

TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck

TypeinterventionalSponsorGroupe Oncologie Radiotherapie Tete et CouRan2014 to 2021Enrolled541ConditionsHead and Neck Squamous Cell CarcinomaArmsCisplatin, 5-Fluorouracile, Docetaxel, Cetuximab, granulocyte colony-stimulating factor (G-CSF)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kevin AtsouCOMPutational Pharmacology and Clinical Oncology Department, Inria Sophia Antipolis - Méditerranée, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France.ORCID 0000-0001-5285-1569
Anne AuperinBiostatistical and Epidemiological Division, Institut Gustave Roussy, Villejuif, France.
Jôel GuigayClinical Oncology, Centre Antoine Lacassagne, Nice, France.
Sébastien SalasCOMPutational Pharmacology and Clinical Oncology Department, Inria Sophia Antipolis - Méditerranée, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France.
Sebastien BenzekryCOMPutational Pharmacology and Clinical Oncology Department, Inria Sophia Antipolis - Méditerranée, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France.ORCID 0000-0002-3749-8637

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We employed a mechanistic learning approach, integrating on-treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post-progression survival (PPS)-the duration from the time of documented disease progression to death-and overall survival (OS) in Head and Neck Squamous Cell Carcinoma (HNSCC). We compared the predictive power of model-derived TK parameters versus RECIST and assessed the efficacy of nine TK-OS ML models against conventional survival models. Data from 526 advanced HNSCC patients treated with chemotherapy and cetuximab in the TPExtreme trial were analyzed using a double-exponential model. TK parameters from the first line and maintenance (TKL1) or after four cycles (TK4) were used to predict PPS and post-cycle 4 OS (OS4), combined with 12 baseline parameters. While ML algorithms underperformed compared to the Cox model for PPS, a random survival forest was superior for OS prediction using TK4 and surpassed RECIST-based metrics. This model demonstrated unbiased OS4 prediction, suggesting its potential for improving HNSCC treatment evaluation. Trial Registration: ClinicalTrials.gov identifier: NCT02268695.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsMachine LearningSquamous Cell Carcinoma of Head and NeckAgedCetuximabFemaleHumansMaleMiddle AgedTreatment OutcomeCetuximabdeep learninghead and neck squamous cell carcinomamachine learningsurvival analysistumor kinetics

Identifiers

PMID39722558
PMCPMC11919269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.